Recent developments in liver pathology.

CONTEXT Hepatocellular carcinoma is the sixth most common malignancy and the third leading cause of cancer deaths worldwide, making pathologic identification of precursor lesions essential. Recent molecular genetic, pathologic, and clinical data have led to the stratification of hepatic adenomas into subgroups with unique molecular profiles and varying potential for malignant transformation, as well as to the reclassification of telangiectatic focal nodular hyperplasia as telangiectatic adenoma. Clinical, morphologic, and molecular genetic studies have also established juvenile hemochromatosis and pediatric nonalcoholic steatohepatitis as entities distinct from their adult counterparts. OBJECTIVE To review the recent molecular genetic characterization of telangiectatic hepatic adenomas and juvenile hemochromatosis, as well as the recent clinicopathologic characterization of pediatric nonalcoholic steatohepatitis. DATA SOURCES Literature review, personal experience, and material from the University of Chicago. CONCLUSIONS Basic science and translational research have led to the classification of many pathologic entities of the liver according to molecular genetic and protein expression profiles that correspond to traditional morphologic categories. Insights into signal transduction pathways that are activated in, and protein expression patterns unique to, an individual disease may lead to the development of new therapeutic agents and novel diagnostic biomarkers.

[1]  Guijing Wang,et al.  Economic burden of obesity in youths aged 6 to 17 years: 1979-1999. , 2002, Pediatrics.

[2]  M. Camilo,et al.  Tamoxifen-associated steatohepatitis--report of three cases. , 1995, Journal of hepatology.

[3]  M. Choti,et al.  Hepatic Adenomas: Analysis of Sex Steroid Receptor Status and the Wnt Signaling Pathway , 2002, Modern Pathology.

[4]  A. Nakagawara,et al.  Two case reports of childhood liver cell adenomas harboring β-catenin abnormalities , 2002 .

[5]  N. Andrews,et al.  Interleukin-6 induces hepcidin expression through STAT3. , 2006, Blood.

[6]  M. Hentze,et al.  STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. , 2007, Blood.

[7]  Cornelia M. van Duijn,et al.  A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis , 2001, Nature Genetics.

[8]  C. Auffray,et al.  HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation* , 2007, Journal of Biological Chemistry.

[9]  J. Zucman‐Rossi.  Genetic alterations in hepatocellular adenomas: recent findings and new challenges. , 2004, Journal of hepatology.

[10]  C. Sirlin,et al.  Pediatric Nonalcoholic Fatty Liver Disease: A Critical Appraisal of Current Data and Implications for Future Research , 2006, Journal of pediatric gastroenterology and nutrition.

[11]  P. Stål,et al.  Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls , 2002, Gut.

[12]  P. Bjorkman,et al.  Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor , 1998, Cell.

[13]  A. Sonnenberg,et al.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. , 1985, The New England journal of medicine.

[14]  R. N. Macsween,et al.  Cirrhosis with steatohepatitis after adjuvant tamoxifen , 1999, The Lancet.

[15]  S. Lepreux,et al.  Multiple telangiectatic focal nodular hyperplasia: vascular abnormalities , 2003, Virchows Archiv.

[16]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[17]  V. Paradis,et al.  Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. , 2004, Gastroenterology.

[18]  R. Chung,et al.  Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. , 2008, Blood.

[19]  A. Donovan,et al.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. , 2005, Cell metabolism.

[20]  M. Cazzola,et al.  Natural history of juvenile haemochromatosis , 2002, British journal of haematology.

[21]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[22]  Yin Xia,et al.  Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. , 2007, The Journal of clinical investigation.

[23]  F. Torti,et al.  Regulation of ferritin genes and protein. , 2002, Blood.

[24]  M. Rashid,et al.  Nonalcoholic steatohepatitis in children. , 2000, Journal of pediatric gastroenterology and nutrition.

[25]  S. Kaneko,et al.  Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. , 2007, Internal medicine.

[26]  H. Greene,et al.  Steatohepatitis in obese children: a cause of chronic liver dysfunction. , 1983, The American journal of gastroenterology.

[27]  T. Saibara,et al.  CYP17 polymorphism and tamoxifen-induced hepatic steatosis. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[28]  N. Andrews,et al.  Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis , 2003, Nature Genetics.

[29]  Marie-Pierre Dubé,et al.  Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis , 2004, Nature Genetics.

[30]  Fritz Haber,et al.  The catalytic decomposition of hydrogen peroxide by iron salts , 1934 .

[31]  Paolo Gasparini,et al.  The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 , 2000, Nature Genetics.

[32]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[33]  P. Bjorkman,et al.  Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor , 2000, Nature.

[34]  S. Daniels.  Regulation of body mass and management of childhood overweight , 2005, Pediatric blood & cancer.

[35]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[36]  K. R. Meyers,et al.  Evidence That Inhibition of Hemojuvelin Shedding in Response to Iron Is Mediated through Neogenin* , 2007, Journal of Biological Chemistry.

[37]  E. Beutler,et al.  Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6 , 2006, Proceedings of the National Academy of Sciences.

[38]  C. Aston,et al.  Familial iron overload with possible autosomal dominant inheritance. , 1990, Australian and New Zealand journal of medicine.

[39]  M. Khoury,et al.  Iron Overload, Public Health, and Genetics: Evaluating the Evidence for Hemochromatosis Screening , 1998, Annals of Internal Medicine.

[40]  R. Wolff,et al.  The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression* , 1997, The Journal of Biological Chemistry.

[41]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[42]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Y. Kohgo,et al.  Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells. , 2000, Biochimica et biophysica acta.

[44]  Gaël Nicolas,et al.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. , 2002, The Journal of clinical investigation.

[45]  D. Häussinger,et al.  Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.

[46]  Harris Pm.  Ferritin: an iron-storage molecule. , 1977 .

[47]  J. Olynyk,et al.  A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. , 2002, Gastroenterology.

[48]  Christian Trautwein,et al.  STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. , 2007, Gastroenterology.

[49]  C. Beaumont,et al.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Rotwein,et al.  Complex biosynthesis of the muscle-enriched iron regulator RGMc , 2006, Journal of Cell Science.

[51]  J. Bilbao,et al.  Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[52]  Clara Camaschella,et al.  Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. , 2008, Blood.

[53]  R. Deutsch,et al.  Influence of Gender, Race, and Ethnicity on Suspected Fatty Liver in Obese Adolescents , 2005, Pediatrics.

[54]  R J Simpson,et al.  A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. , 2000, Molecular cell.

[55]  D. Engelkamp,et al.  Isolation and expression pattern of three mouse homologues of chick Rgm. , 2004, Gene expression patterns : GEP.

[56]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.

[57]  M. Kay,et al.  Distinct pathways of genomic progression to benign and malignant tumors of the liver , 2007, Proceedings of the National Academy of Sciences.

[58]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[59]  D. Purdie,et al.  Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis , 2003, The Lancet.

[60]  S. Hirohashi,et al.  Overexpression of orphan G‐protein–coupled receptor, Gpr49, in human hepatocellular carcinomas with β‐catenin mutations , 2003, Hepatology.

[61]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[62]  T. Ganz,et al.  Hepcidin is decreased in TFR2 hemochromatosis. , 2005, Blood.

[63]  S. Abboud,et al.  A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism* , 2000, The Journal of Biological Chemistry.

[64]  Jeffrey B. Schwimmer,et al.  Prevalence of Fatty Liver in Children and Adolescents , 2006, Pediatrics.

[65]  A. Donovan,et al.  Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. , 2001, The Journal of clinical investigation.

[66]  Raymond T Chung,et al.  Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression , 2006, Nature Genetics.

[67]  A. Perez-Atayde,et al.  Idiopathic steatohepatitis in childhood: a multicenter retrospective study. , 1995, The Journal of pediatrics.

[68]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[69]  J. Zucman‐Rossi,et al.  Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. , 2005, Gastroenterology.

[70]  O. Aruoma,et al.  Damage to the bases in DNA induced by hydrogen peroxide and ferric ion chelates. , 1989, The Journal of biological chemistry.

[71]  E. Simpson,et al.  Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. , 2004, Endocrinology.

[72]  J. Barton,et al.  Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. , 2004, Blood.

[73]  V. Paradis,et al.  Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X‐chromosome inactivation , 1997, Hepatology.

[74]  Thomas Walz,et al.  Structure of the Human Transferrin Receptor-Transferrin Complex , 2004, Cell.

[75]  A. Dautry‐Varsat,et al.  Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Kirsch,et al.  Rodent nutritional model of non‐alcoholic steatohepatitis: Species, strain and sex difference studies , 2003, Journal of gastroenterology and hepatology.

[77]  K. Hveem,et al.  Hereditary hemochromatosis: the clinical significance of the S65C mutation. , 2002, Genetic testing.

[78]  B. Taouli,et al.  Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases. , 2003, Radiology.

[79]  A. Brownlie,et al.  Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter , 2000, Nature.

[80]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[81]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[82]  Stephan Nussberger,et al.  Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.

[83]  W. Dietz,et al.  Overweight in childhood and adolescence. , 2004, The New England journal of medicine.

[84]  N. Andrews,et al.  Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene , 1997, Nature genetics.

[85]  S. Goldstein,et al.  The Fenton reagents. , 1993, Free radical biology & medicine.

[86]  C. Finch,et al.  IDIOPATHIC HEMOCHROMATOSIS, AN IRON STORAGE DISEASE: A. Iron Metabolism in Hemochromatosis , 1955, Medicine.

[87]  C. Degott,et al.  Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. , 1999, The American journal of surgical pathology.

[88]  T. Saibara,et al.  Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. , 2000, The Journal of clinical investigation.

[89]  P. Rotwein,et al.  Pro-protein convertases control the maturation and processing of the iron-regulatory protein, RGMc/hemojuvelin , 2008, BMC Biochemistry.

[90]  K. Alberti,et al.  Impaired glucose tolerance: what are the clinical implications? , 1998, Diabetes research and clinical practice.

[91]  Y. Jeng,et al.  p53 gene and Wnt signaling in benign neoplasms: β‐catenin mutations in hepatic adenoma but not in focal nodular hyperplasia , 2002, Hepatology.

[92]  J. Gitlin,et al.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Jong-Wan Park,et al.  ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. , 2007, Biochemical and biophysical research communications.

[94]  A. J. Bourne,et al.  Non‐alcoholic steatohepatitis in children and adolescents , 2000, The Medical journal of Australia.

[95]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[96]  B. Cesana,et al.  Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis , 1992, Hepatology.

[97]  W. Sly,et al.  Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[98]  V. Nizet,et al.  Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). , 2007, The Journal of clinical investigation.

[99]  R. Rosenblatt,et al.  Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. , 1979, Gastroenterology.

[100]  Y. Nakamura,et al.  Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. , 1998, Cancer research.

[101]  J. Saffitz,et al.  A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. , 1998, The Journal of clinical investigation.

[102]  Y. Ogawa,et al.  Tamoxifen-induced fatty liver in patients with breast cancer , 1998, The Lancet.

[103]  C. Beaumont,et al.  Severe iron deficiency anemia in transgenic mice expressing liver hepcidin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Laura Maffei,et al.  Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. , 2004, The Journal of clinical endocrinology and metabolism.

[105]  Christina H. Park,et al.  Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.

[106]  M. Buendia,et al.  Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. , 1999, The American journal of pathology.

[107]  O. Aruoma,et al.  Iron ion-dependent modification of bases in DNA by the superoxide radical-generating system hypoxanthine/xanthine oxidase. , 1989, The Journal of biological chemistry.

[108]  D. Girelli,et al.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis , 2003, Nature Genetics.

[109]  W. Burke,et al.  HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. , 2001, American journal of epidemiology.

[110]  R. Deutsch,et al.  Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. , 2003, The Journal of pediatrics.